spacer
home > > autumn 2018 > right first and every time
PUBLICATIONS


Right First and Every Time

In recent years, a number of regulatory agencies, scientific bodies, and healthcare organisations have introduced many initiatives to improve the effectiveness and quality of clinical research. However, challenges are still evident when it comes to balancing safety and efficiency in clinical research. Thus, it has been repeatedly stated that better quality management and a different approach is needed urgently. Evolution needs to be driven for safer, more effective clinical research based on principles of minimising harm, removing waste, and managing variation. This requires a more systematic approach.

Good Clinical Practice (GCP) guidelines are simply not enough to ensure safety nowadays. One of the reasons for this is that these are regulations that offer the workflow of documentation and the structure of clinical trials, but the control over how people are implementing them is far too low. To address this challenge, developing standardisation processes of the investigator sites and a database of these accredited sites came into effect in many clinical trials. This standardisation covers all aspects of documentation, patient engagement, and professional qualification of the organisation, where the clinical trials are going to be conducted. Instead of focussing only on the way the site follows ICH GCP regulation, the efficiency profile of the investigator sites will need to be ensured.

Appropriate, proportionate standards that focus on the things that matter are necessary. Beyond any revisions to the existing guidelines or the creation of new sets of guidance, wider cultural change is required to ensure that guidance is implemented appropriately.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Suzanne Pavon is Chief Quality and Compliance Officer, Executive Vice President of Quality Management, Corporate Compliance, and Legal at TFS. Suzanne is an entrepreneurial leader and senior executive with over 20 years’ global experience in the pharmaceutical, biotechnology, and CRO industry. Previous roles include a number of senior leadership positions in quality management, compliance, and clinical operations. She has worked at Novartis, Clinigen, uniQure, Teva, Sanofi, and Genzyme, including five years working at Mayo Clinic, US, and the King Hussain Cancer Center, Jordan. Suzanne is a graduate of Philadelphia University, US, and Harvard School of Public Health, US, and has earned a PhD in oncology, a PharmD, and Certified Professional in Healthcare Quality status.
spacer
Dr Suzanne Pavon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IMFINZITM (durvalumab) WITH CHEMOTHERAPY DEMONSTRATED A SUSTAINED OVERALL SURVIVAL BENEFIT IN 1ST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN THE PHASE III CASPIAN TRIAL

Detailed results from an updated analysis of the Phase III CASPIAN trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement